Lineage Cell Therapeutics, Inc.LCTXNYSE
LOADING
|||
Year-over-year net income growth rate
| Period | Value |
|---|---|
| Q3 2025 | 2.24% |
| Q2 2025 | -636.02% |
| Q1 2025 | -26.46% |
| Q4 2024 | -7.88% |
| Q3 2024 | 47.33% |
| Q2 2024 | 11.95% |
| Q1 2024 | -37.01% |
| Q4 2023 | 32.84% |
| Q3 2023 | -35.97% |
| Q2 2023 | -19.60% |
| Q1 2023 | 31.19% |
| Q4 2022 | -4.70% |
| Q3 2022 | 10.26% |
| Q2 2022 | 4.57% |
| Q1 2022 | 75.55% |
| Q4 2021 | -270.57% |
| Q3 2021 | -63.39% |
| Q2 2021 | -238.14% |
| Q1 2021 | -169.69% |
| Q4 2020 | 126.19% |
| Q3 2020 | -18.98% |
| Q2 2020 | 22.35% |
| Q1 2020 | -87.39% |
| Q4 2019 | 72.84% |
| Q3 2019 | 45.04% |
| Q2 2019 | -176.40% |
| Q1 2019 | 187.45% |
| Q4 2018 | -167.37% |
| Q3 2018 | 1683.04% |
| Q2 2018 | 93.37% |
| Q1 2018 | 11.66% |
| Q4 2017 | -602.30% |
| Q3 2017 | 222.92% |
| Q2 2017 | -123.64% |
| Q1 2017 | 1071.00% |
| Q4 2016 | -116.27% |
| Q3 2016 | 27.09% |
| Q2 2016 | 243.46% |
| Q1 2016 | -27.47% |
| Q4 2015 | 1.48% |